Labcorp Holdings Inc.

NYSE:LH

Medical - Diagnostics & Research

Healthcare
$370.78 -1.33%

-$3.46 today

Market cap
$30.11B
Beta
0.88
P/E (TTM)
22.4
EPS (TTM)
$11.44
Dividend yield
1.12%
52W Low $241.81High $293.72

Volume 0.69M

Average 0.63M

LH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Labcorp Holdings Inc.NYSE: LH

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $299.1M rose 25.5% year over year, behind the +31.3% change in trailing-twelve-month net income. Sequentially, it rose 7.6% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Net income amounted to 6.3% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of $1.55B (+76.3%) for the fiscal year ending Dec 2026, a step up from the +17.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$299.1M+7.6% QoQ
Last fiscal yearDec 2025
$877.7M+17.7% YoY
LTMJun 2026
$1B+31.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.5%+44.9%+19.4 pp
1 year+17.7%+76.3%+58.6 pp
3-year CAGR-4.4%+28.0%+32.4 pp
5-year CAGR+20.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
877.7M USD
Year-over-year change
+17.7%
4-year CAGR
-22.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How LH compares with its peers on the latest reported figures

  • LH's LTM Jun 2026 net income of $1B is the 3rd largest of the 7 companies compared; the peer median is $108.49M.
  • Its year-over-year change of +31.3% is the highest of 7, against a peer median of +8.8%.
  • Net income amounts to 7.0% of revenue for LH, versus a peer median of 17.2%.
LH Competitors Peer median
Net Income for LH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$7.09B +7.9%-1.2%15.0%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$1.17B +15.5%+1.0%9.9%
LHLabcorp Holdings Inc.LTM Jun 2026$1B +31.3%-4.4%7.0%
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
QGENQiagen N.V.LTM Jun 2026$409.32M +9.6%+0.1%19.5%
GRALGRAIL, Inc.LTM Jun 2026$391.59M -11.6%-57.7%236.9%
NTRANatera, Inc.LTM Jun 2026$192.35M -24.0%-27.6%7.1%
Peer median (excluding LH) $108.49M+8.8%-7.6%17.2%

Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.38B1B379.2M746M877.7M
Depreciation & Amortization577M537.2M577.3M643.5M681.1M
Deferred Income Tax(37.3M)26.3M(78.1M)(20.1M)97.6M
Stock-Based Compensation132.9M116.8M128.7M116.7M125.8M
Change in Working Capital(263.7M)(603.4M)(361.9M)(154.1M)(526.1M)
Accounts Receivables222M15.9M(75.3M)98.5M(122.2M)
Inventory2.8M(45.5M)(700K)(14.6M)(30.2M)
Accounts Payables(10.2M)307.1M(42.4M)210.3M(52.8M)
Other Working Capital(478.3M)(880.9M)(243.5M)(448.3M)(320.9M)
Other Non-Cash Items321.2M875.5M682.5M253.8M384.4M
Operating Cash Flow3.11B1.96B1.33B1.59B1.64B
Capital Expenditures(460.4M)(481.9M)(453.6M)(489.9M)(434.5M)
Acquisitions (Net)(496.9M)(1.16B)(671.5M)(823.9M)(582M)
Purchases of Investments(27.8M)(17.4M)(29M)(55M)(192.4M)
Sales of Investments13.2M8.1M6.7M06.9M
Other Investing Activities87.3M1.4M(24.1M)2M8M
Investing Cash Flow(884.6M)(1.65B)(1.17B)(1.37B)(1.19B)
Debt Repayment(375M)0(300M)1B(775M)
Common Stock Issued51.7M50.6M0054.3M
Common Stock Repurchased(1.67B)(1.15B)(1.04B)(250.1M)(450M)
Dividends Paid0(195.2M)(254M)(243.1M)(240.7M)
Other Financing Activities(74M)23.6M1.53B273.1M(45.6M)
Financing Cash Flow(2.07B)(1.32B)(59.3M)779.9M(1.46B)
Effect of Forex Changes(7.3M)(24.2M)9.9M(17M)24.1M
Net Change in Cash151.9M(1.04B)106.8M981.9M(986.4M)
Free Cash Flow2.65B1.47B874.1M1.1B1.21B

Labcorp Holdings Inc.

NYSE:LH

Intrinsic Alpha fair value

Locked

Current Price

$370.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.